Nurix Therapeutics plans oral presentation on multiple degrader programs at San Diego conference

Nurix Therapeutics plans oral presentation on multiple degrader programs at San Diego conference
Nurix Therapeutics unveils preclinical data

Nurix Therapeutics announced plans to present multiple research abstracts, including an oral presentation detailing preclinical data from several of its degrader programs, at the upcoming AACR26 Annual Meeting in San Diego scheduled for April 17–22.

The company will showcase recent advancements in its targeted protein degradation pipeline, underscoring its continued focus on expanding the range of potential therapeutic applications for cancer and other diseases. Nurix Therapeutics has invited interested parties to learn more about these findings during the conference.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.